Silexion Therapeutics Corp (SLXN)

Augmedix Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2013	FY 2012
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2013	Dec 31, 2012
Cash & Equivalents	1.19	4.6	0.79	1.6
Cash & Short-Term Investments	1.19	4.6	0.79	1.6
Cash Growth	-74.17%	483.12%	-50.69%	-
Other Receivables	-	-	0.09	0.16
Receivables	-	-	0.09	0.16
Prepaid Expenses	0.97	0.34	0.01	-
Restricted Cash	0.04	0.03	-	-
Other Current Assets	0.06	0.02	0.04	0.03
Total Current Assets	2.25	4.98	0.93	1.79
Property, Plant & Equipment	0.56	0.25	0.01	0.01
Other Long-Term Assets	0.05	0.03	-	-
Total Assets	2.86	5.26	0.94	1.8
Accounts Payable	0.93	0.32	0.1	0.08
Accrued Expenses	1.43	1.57	0.14	0.09
Short-Term Debt	1	-	-	-
Current Portion of Leases	0.16	0.11	-	-
Other Current Liabilities	0	0.2	-	-
Total Current Liabilities	3.52	2.2	0.24	0.17
Long-Term Debt	2.96	-	-	-
Long-Term Leases	0.37	0.06	-	-
Total Liabilities	6.85	2.26	0.24	0.17
Common Stock	0	-	-	-
Additional Paid-In Capital	39.26	11.34	5.16	4.74
Retained Earnings	-43.25	-26.81	-4.47	-3.11
Total Common Equity	-3.99	-15.48	0.7	1.63
Minority Interest	-	3.42	-	-
Shareholders' Equity	-3.99	3	0.7	1.63
Total Liabilities & Equity	2.86	5.26	0.94	1.8
Total Debt	4.49	0.17	-	-
Net Cash (Debt)	-3.3	4.42	0.79	1.6
Net Cash Growth	-	461.42%	-50.69%	-
Net Cash Per Share	-79.44	-	-	-
Filing Date Shares Outstanding	0.56	-	-	-
Total Common Shares Outstanding	0.12	-	-	-
Working Capital	-1.27	2.78	0.69	1.62
Book Value Per Share	-32.37	-	-	-
Tangible Book Value	-3.99	-15.48	0.7	1.63
Tangible Book Value Per Share	-32.37	-	-	-
Machinery	0.1	0.08	0.02	0.01
Leasehold Improvements	-	0.06	-	-

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q